The Israel BioToken Factory Initiative, announced on July 12, 2026, will put NIS 70 million from the Israel Innovation Authority behind a shared national platform for biological artificial intelligence, according to the IBFI announcement and named partner list. The consortium pairs NVIDIA, Teva Pharmaceutical Industries, and Sheba Medical Center with three life-sciences startups, CytoReason, TerraCyte Analytics, and MeMed, alongside researchers from the Weizmann Institute of Science, the Technion, and Ben-Gurion University of the Negev.
The IBFI is built around a common technology platform that the authority says will let companies, researchers, and healthcare organizations build AI models on biological data through a single shared stack. The framing positions the consortium as a national pre-competitive R&D infrastructure, the same term the authority uses for the wider Israeli life sciences ecosystem the IBFI is meant to serve.
What the IBFI Will Build
The July 12 release describes a shared platform with two named technical components and an initial list of clinical and research targets where the platform will be tested first. The platform is meant to give companies, researchers, and healthcare organizations a common way to build the next generation of AI models based on biological data, in the authority’s wording. That wording is the heart of the announcement: it positions the IBFI as a research platform, not a research project.
It is also a national-level bet, framed in Jerusalem by Gila Gamliel, the Minister of Innovation, Science and Technology, who called the IBFI an investment in health, the economy, and the future of Israel. The framing matters because the consortium is not framed as a startup incubator or a one-off grant. It is positioned as shared research infrastructure, the kind of pre-competitive stack the authority says will serve the entire Israeli life sciences ecosystem. The authority’s own language of a unique Israeli infrastructure of global caliber sets the ambition at the level of an ecosystem standard. The stated aim is that the IBFI becomes the common layer that any Israeli life-sciences company can build on top of.
Bio Tokens and the Factory Model
At the technical core, the IBFI rests on two pieces. The first, called Bio Tokens, is meant to act as a standardized representation layer for different kinds of biological data. The second, the Factory Model, is the platform on top of it, where AI-based biological models are developed, integrated, run, and made accessible. The two pieces are described in the press release as a way to “connect molecular, cellular, dynamic, and clinical data within a single computational framework.”
| Component | What it does |
|---|---|
| Bio Tokens | Standardized representation layer for different types of biological data |
| Factory Model | Platform for the development, integration, execution, and accessibility of AI-based biological models |
Yoav Nissan Cohen, the consortium’s chairman and the CEO and chairman of TerraCyte, framed the two pieces in plain terms. “Biology still does not speak a language that AI can understand,” he said, and the IBFI exists to build both the infrastructure and the language on which the next generation of biological AI will be based. The two components together are meant to connect molecular, cellular, dynamic, and clinical data inside one computational framework, per the press release. The standardized representation layer is the part that lets different kinds of biological data talk to the same model. The platform on top of it is the part where those models get built, integrated, and run.
What the press release commits to is a unified computational framework for connecting molecular, cellular, dynamic, and clinical data. What it does not yet specify is how the Bio Tokens and Factory Model components will be exposed to users outside the six named industry partners. The IBFI’s national-platform framing assumes broad adoption, but the operational details of who can access the shared layers are not in the July 12 release.
Six Industry Partners
NVIDIA, Teva Pharmaceutical Industries, and Sheba Medical Center are the three anchor industry partners, joined by three life-sciences startups: CytoReason, TerraCyte Analytics, and MeMed. NVIDIA’s BioNeMo platform for AI-driven biology is one of the more established stacks for AI-driven biology and drug discovery. Sheba Medical Center’s AI center for medicine at Sheba Medical Center brings patient data and clinical validation pathways into the consortium. Teva, named by the authority as a partner, brings pharmaceutical industry scale to the IBFI.
- NVIDIA: Chipmaker behind BioNeMo, an established stack for AI-driven biology and drug discovery.
- Teva Pharmaceutical Industries: Pharmaceutical industry anchor, named by the authority as a partner.
- Sheba Medical Center: Clinical anchor, with an existing AI center for medicine.
- CytoReason: AI disease-models startup, co-founded by Shen-Orr.
- TerraCyte Analytics: Startup chaired by the IBFI’s chairman.
- MeMed: Diagnostics firm, listed by the authority as a partner.
The roster mixes three anchor partners (NVIDIA, Teva, and Sheba) with three startups (CytoReason, TerraCyte Analytics, and MeMed), and three universities (Weizmann, Technion, and Ben-Gurion). The three startups are listed as partners alongside the anchors and the universities, with the press release describing them collectively as partners without specifying a per-startup role. The arrangement puts established academic and industry scale on one side and earlier-stage startups on the other. The authority has cast the arrangement as “pre-competitive,” meaning the outputs are meant to be shared across the Israeli life sciences ecosystem.
Each of the three anchor partners brings a different kind of scale to the consortium. NVIDIA is the chipmaker behind CUDA and the BioNeMo platform for AI-driven biology and drug discovery. Teva Pharmaceutical Industries is the pharmaceutical industry anchor named in the press release. Sheba Medical Center is a large Israeli hospital with an existing AI center for medicine. The three startups round out the industry roster, and the press release describes them as partners without specifying a per-startup role.
The consortium has not named a CEO or executive director, and the July 12 release does not specify who runs day-to-day program management. Cohen is the chairman, the four scientific leads are listed without operational titles, and the IIA is named as the body that announced the IBFI’s establishment. The arrangement leaves the consortium without a publicly named executive team. How that governance arrangement plays out for delivery speed will depend on the operational details the authority has not yet published.
Four Investigators Across Three Universities
Prof. Eran Segal, a computational biologist at the Weizmann Institute of Science whose lab has built AI models for personalized medicine and the gut microbiome, is one of the four principal investigators the IBFI names, alongside Prof. Nir Yosef, who works on systems immunology at the same institution. Prof. Shai Shen-Orr, head of the Systems Immunology and Precision Medicine Laboratory at the Technion and a co-founder and chief scientist of CytoReason, one of the consortium’s startup partners, is the third. Prof. Assaf Zaritsky, of the Institute for Interdisciplinary Computational Science at Ben-Gurion University of the Negev, is the fourth.
The four investigators collectively span the three universities the IBFI explicitly names. The arrangement places Shen-Orr’s dual role as CytoReason’s chief scientist inside the same consortium that includes CytoReason as a partner. The press release does not publish any conflict-of-interest disclosures or recusal procedures for the named investigators. Cohen’s joint role at the IBFI and at TerraCyte puts a similar dual-role question on the chairman’s side.
Seven First-Wave Targets in Disease and Drug Discovery
The IBFI’s first applications are expected to focus on seven areas, drawn from the consortium’s stated mandate. The list reads as a starting point for biological AI, not a final scope.
- Predicting responses to oncology treatments
- Evaluating immune system activity
- Predicting drug hypersensitivity
- Supporting clinical decision-making in sepsis
- Assessing transplant rejection
- Autoimmune diseases
- Drug discovery
The seven areas span most of the consortium’s stated clinical focus. Predicting responses to oncology treatments and evaluating immune system activity are the two largest disease categories on the list. Drug hypersensitivity and sepsis clinical decision-making are both areas where Sheba’s clinical data could anchor the work. Transplant rejection and autoimmune diseases are the two immunology-heavy entries, and drug discovery sits at the bottom as the broadest catch-all.
The press release describes these as the “initial applications” the IBFI is expected to focus on, with the hedge “among other areas,” so the seven-item list is presented as a starting point, not a complete roster. What the July 12 release does not include is a per-workstream budget, an order of operations, or a delivery date for any of the seven. The authority has not said whether each workstream will be led by one of the four named scientific leads, or whether some will run inside individual partner organizations. The IBFI’s national-platform framing assumes the seven will be tackled in parallel rather than sequenced, but the announcement leaves that decision open. Until the consortium publishes its first milestone list, the seven target areas function as a public statement of intent rather than a project plan.
A Pre-Competitive Pitch for Shared Infrastructure
The new consortium will develop a unique Israeli infrastructure of global caliber that will enable standardized representation of biological data, integration of prior biological knowledge, development of computational disease models, and clinical validation of the resulting outputs.
The statement above is from Dror Bin, CEO of the Israel Innovation Authority, in the IBFI announcement of July 12, 2026. It is the architectural premise of the consortium, and it borrows from how other industries have organized their own shared layers. The pitch is that standardized infrastructure beats one-off stacks inside each lab.
In semiconductors, the move from proprietary fabs to shared foundries unlocked a generation of chip designers who no longer had to own a fab. In large language models, the move from one-off research code to shared open-weight releases let downstream teams build products on top of common models. The IBFI’s pitch is the same shape for biological AI: build a shared layer once, and let many companies build on top. Cohen, who chairs both the consortium and TerraCyte, put the same idea in plainer language. He described biology as a system that does not yet speak a language AI can understand, and said the IBFI exists to build both the infrastructure and the language on which the next generation of biological AI will be based.
The combination is what the authority means by “shared, pre-competitive R&D infrastructure,” a term Bin used twice in the announcement. Pre-competitive, in this context, means outputs are designed to be shared across the Israeli life sciences ecosystem, not enclosed inside any single partner. Tools and standards built inside the consortium will, in principle, be available to any Israeli life-sciences company, not just the six named industry partners. The framing matters because it dictates how the IBFI’s outputs are licensed and who can build on top.
The NIS 70 million investment is, in effect, a public bet on the pre-competitive model. Whether the bet pays off depends on what the consortium ships first, and on whether the seven target applications translate into published tools that are usable beyond partner labs. The authority’s framing leaves the comparison to other shared bio-AI infrastructure efforts elsewhere for later announcements.
The IBFI’s pitch is to put three anchor partners, three startups, and four principal investigators inside the same consortium from day one, rather than building each layer separately. The authority’s framing of national infrastructure is a signal that the consortium is meant to outlive any single grant cycle. That kind of durability usually depends on stable governance, multi-year funding, and clear licensing for shared outputs. The July 12 release includes none of those details.
What the Announcement Leaves Out
The July 12 release covers the consortium’s formation, its named partners, and its stated mandate. It does not include a project schedule, a milestone list, or a delivery date for either the Bio Tokens or Factory Model components. It does not name a hub institution beyond Sheba Medical Center for clinical validation. And it does not break down how the NIS 70 million will be split between the authority’s grant and any in-kind contributions from NVIDIA, Teva, Sheba, and the three startup partners. The release also lists the seven target areas with the hedge “among other areas,” signaling more may come later but not naming them.
The release also does not say who owns the intellectual property that comes out of the consortium, or how the shared outputs will be licensed outside the six named partners. The authority’s framing of the IBFI as a “shared, pre-competitive R&D infrastructure” implies open or at least broadly licensed outputs, but the press release does not put that in operational terms. Those terms matter because they determine whether a startup outside the six named partners can build a product on top of the Bio Tokens layer without negotiating access. The press release also does not name a CEO, an executive director, or a day-to-day program manager for the consortium.
What the IBFI does include is a starting list of clinical targets and four named principal investigators with track records in computational biology, systems immunology, and AI-driven disease modeling. Whether the consortium’s outputs end up as published standards or as internal infrastructure for the six named partners will depend on the operational details the July 12 release has not yet supplied. The authority has signaled that further announcements are coming, but none of them were attached to the July 12 release.
